935106861
info@markelab.com
Precio
350€ (100 µg)
ATP-Dependent Translocase ABCB1 (ABCB1) Antibody is a Rabbit Polyclonal antibody for the detection of P Glycoprotein. ABCB1 (also known as P-gp/ P-glycoprotein, MDR1/multidrug-resistance 1) is a plasma membrane protein first discovered in multidrug resistant tumor cells. ABCB1 can extrude a large number of medically relevant compounds from cells and causes drug resistance. ABCB1 is expressed in a variety of human cancers as well as normal tissues including brain, and placenta. Overexpression of ABCB1 correlates with a negative prognosis in several types of cancer.
ABCB1, also known as P-glycoprotein, is a well-studied ATP-dependent efflux transporter involved in the transport of a wide range of substrates, including drugs, lipids, and xenobiotics. It is highly expressed in barrier tissues, such as the blood-brain barrier, intestines, liver, and kidneys, where it functions to protect tissues by actively exporting toxic compounds and drugs. ABCB1 plays a crucial role in pharmacokinetics, influencing drug absorption, distribution, and elimination. Overexpression of ABCB1 in cancer cells is a major contributor to multidrug resistance, as it pumps chemotherapeutic agents out of cells, reducing their efficacy. Structurally, ABCB1 contains two transmembrane domains and two ATP-binding domains, which utilize ATP hydrolysis to drive substrate transport. Its pivotal role in drug resistance and detoxification makes it a significant target in cancer therapy and pharmacological research.
Primary Antibodies
Polyclonal
Human, Mouse
ATP-Dependent Translocase ABCB1 (ABCB1)
Rabbit
Unconjugated
Liquid
ELISA, WB, IHC, IP
≥ 95% (SDS-PAGE)
Purified by immunogen affinity chromatography.
PBS, pH 7.3, with 0.02% sodium azide and 50% glycerol.
100 µg
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
ABCB1
No
Shipped within 5-12 working days.
ABC20,CD243,CLCS,GP170,MDR1,P-GP,PGY1,p-170
This product is for research use only.
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más